PRAMIPEXOLE DIHYDROCHLORIDE LOADED MPEGPCL NANOSUSPENSION BY MODIFIED NANOPRECIPITATION: IN VITRO AND IN VIVO EVALUATION
DOI:
https://doi.org/10.22159/ajpcr.2016.v9i6.13979Abstract
Abstract
Aim and Objectives The present study was carried out to show the potential neuroprotective effects in both invitro and invivo pramipexole dihydrochloride nanosuspension for the treatment in Parkinson's disease.
Materials and Methods: Nanosuspension of pramipexole dihydrochloride was prepared with MPEG-PCL and Pluronic F68 by the process of modified nanoprecipitation technique with different concentrations of MPEG-PCL. The particle size, zeta potential, SEM, TEM and invitro dug release where performed. The cell viability study was performed by using SH-SY5Y cells. Further the formulation is evaluated for its antioxidant potential against rotenone induced neuronal damage in Wister rats such as enzymatic, non enzymatic antioxidants and histopathological evaluation.
Result and Discussion: The nanoformulation shows least particle size of 143 nm and maximum zeta potential value 33.4 mv with 88.53% entrapment efficiency were observed with PMPNP 2 formulation. The SEM, TEM and invitro dug release of PMPNP 2 were shows spherical shape with controlled release when compared to other formulations. Further the MTT assay were performed by using SH-SY5Y cells which shows more than 50 % cell viability with 50 µl of PPMNP 2 nanoformulation. Further the antioxidant potential done in rotenone induced neuronal damage in Wister rats. The results showed elevation in the levels of enzymatic and non enzymatic antioxidants compared with neuronal toxic group. Further nanoformulation group showed decrease in levels of LPO which correlates with histopathological architecture.
Conclusion: Our study concluded that nanoformulation showed better protective potential in both invitro and invivo compare to free drug for the treatment in Parkinson's disease.
Keywords: Pramipexoledihydrochloride; MPEG-PCL; SH-SY5Y cells; Nanoprecipitation; Parkinson's disease.
Downloads
References
Huang R, Ma H, Guo Y, Liu S, Kuang Y, Shao K, et al. Angiopep-
Table 6: The GSH and LPO levels of rat brain in experimental animals
Groups
Parameters
(μmole/mg protein)
LPO
GSH
Group A (control)
46±0.012
52±0.050
Group B
18±0.015
11±0.041
Group C
40±0.004
42±0.035
Group D
43±0.006
52±0.027
±SD mean p<0.05. GSH: Glutathione, LPO: Lipid peroxidationconjugated nanoparticles for targeted long-term gene therapy of Parkinson’s disease. Pharm Res 2013;30(10):2549-59.
Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res 2008;1200:159-68.
Jaber M, Robinson SW, Missale C, Caron MG. Dopamine receptors and brain function. Neuropharmacology 1996;35(11):1503-19.
Neha B, Ganesh B, Preeti K. Drug delivery to the brain using polymeric nanoparticles: A review. Int J Pharm Life Sci 2013;2(3):107-32.
Wang JX, Sun X, Zhang ZR. Enhanced brain targeting by synthesis of 3’, 5’-dioctanoyl-5-fluoro-2’-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002;54(3):285-90.
Esposito E, Mariani P, Ravani L, Contado C, Volta M, Bido S, et al. Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study. Eur J Pharm Biopharm 2012;80(2):306-14.
Trapani A, De Giglio E, Cafagna D, Denora N, Agrimi G, Cassano T, et al. Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm 2011;419(1-2):296-307.
Tamilselvam K, Nataraj J, Janakiraman U, Manivasagam T, Essa MM. Antioxidant and anti-inflammatory potential of hesperidin against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced experimental Parkinson’s disease in mice. Int J Nutr Pharmacol Neurol Dis 2013;3(3):294.
Shrinidh AJ, Sandip SC, Krutika KS. Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 2010;76:189-99.
Huang R, Ma H, Guo Y, Liu S, Kuang Y, Shao K, et al. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of Parkinson’s disease. Pharm Res 2013;30(10):1-11.
Jana U, Mohanty AK, Pal SL, Manna PK, Mohanta GP. Preparation and in vitro characterization of Felodipine loaded Eudragit® Rs100 nanoparticles. Int J Pharm Pharm Sci 2014;6(4):564-7.
Athira Gk, Jyothi AN. Preparation and characterization of curcumin loaded cassava starch nanoparticles with improved cellular absorption. Int J Pharm Pharm Sci 2014;6(10):171-6.
Somasundaram I, Yadav BV, Kumar SS. Formulation of plga polymeric nanosuspension containing pramipexole dihydrochloride for improved treatment of Parkinson’s diseases, research. J Pharm Tech 2016;9(7):810-6.
Bilati U, Allémann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci 2005;24(1):67-75.
Yadav KS, Sawant KK. Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles, AAPS PharmSciTech 2010;11(3):1456-65.
Rajan M. Raj V. Encapsulation, characterisation and in vitro release of anti-tuberculosis drug using chitosan - poly ethylene glycol nanoparticles. Int J Pharm Pharm Sci 2012;4(4):255-9.
Kura AU, Ain NM, Hussein MZ, Fakurazi S, Hussein-Al-Ali SH. Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson’s disease model. Int J Mol Sci 2014;15:5916-27.
Morais LH, Lima MM, Martynhak BJ, Santiago R, Takahashi TT, Ariza D, et al. Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone
administration. Pharmacol Rep 2012;64(5):1081-90.
Durak I, Canbolat O, Kavutcu M, Ozturk HS, Yurtarslani Z. Activities of total cytoplasmic and mitochondrial superoxide dismutase enzymes in sera and pleural fluids from patients with lung cancer. J Clin Lab Anal 1996;10(1):17-20.
Aebi H. Catalase. In: Packer L, editor. Methods in Enzymology. Orlando, FL: Academic Press; 1984. p. 125-6.
Flohé L, Günzler WA. Assays of glutathione peroxidase. Methods Enzymol 1984;105:114-21.
Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980;106(1):207-12.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxidation in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95(2):351-8.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
